Beyond Trial Termination: What InflaRx's Vilobelimab Data Really Tells Us About Pyoderma Gangrenosum Treatment

When InflaRx halted its Phase 3 study of Vilobelimab in pyoderma gangrenosum last May, it looked like another clinical disappointment. But the company’s deeper dive into the full dataset is painting a more nuanced picture—one that may reshape how the biotech community views this rare skin disease.

The Problem: Why Pyoderma Gangrenosum Needs New Solutions

Pyoderma gangrenosum remains a clinical nightmare. This rare, ulcerative neutrophilic skin condition causes severe, non-healing wounds that leave patients in chronic pain with virtually no FDA-approved treatment options. The disease represents a significant unmet need, yet it’s been largely overlooked in drug development. InflaRx’s Phase 3 trial was groundbreaking as the first randomized, placebo-controlled study to target the C5a/C5aR pathway in this indication.

Reading Between the Lines: What the Secondary Data Reveals

While Vilobelimab missed its primary endpoint of complete target ulcer closure, the story doesn’t end there. With 54 patients enrolled and 30 completing six months of treatment, secondary outcomes tell a compelling story:

• Complete disease remission occurred in 20.8% of patients on Vilobelimab versus just 5.6% receiving placebo—a nearly fourfold difference
• Meaningful ulcer volume reduction (>50%) was achieved by 36.4% of Vilobelimab recipients compared to 16.7% in the placebo arm
• Quality of life improvements were substantial, with Dermatology Life Quality Index scores dropping 31.1% for treated patients while slightly worsening in placebo recipients

These aren’t marginal differences. They suggest the mechanism is working, but perhaps the endpoint definition or treatment duration needs recalibration.

The Technical Vindication

Post-hoc statistical analyses strengthened the case further. Mixed model repeated measures analysis demonstrated significant reductions in ulcer volume from week 14 through week 26 favoring Vilobelimab. Covariance analyses confirmed statistically significant improvements in both ulcer volume and surface area. This consistency across analytical approaches suggests genuine treatment effect rather than statistical noise.

Safety remained favorable, with adverse events predominantly mild to moderate—important for a patient population already suffering.

Why Early Termination Might Have Been Premature

The independent monitoring board recommended stopping based on interim data from the first 30 patients. However, the full dataset tells a different story. This raises questions about whether earlier stopping rules were too stringent for a rare disease where signal detection naturally requires larger samples and longer observation periods.

Next Steps: Partnership and Pathway Exploration

InflaRx plans to engage the FDA about alternative endpoint definitions more suitable for pyoderma gangrenosum. Notably, the company signals that future development will likely require a partner, as internal resources are now concentrated on advancing Izicopan (INF904), its oral C5aR inhibitor.

Vilobelimab’s GOHIBIC formulation continues generating modest revenue from COVID-19 and ARDS applications (€39,000 from U.S. COVID sales in the first half of 2025), but the pyoderma gangrenosum chapter appears to require external collaboration to continue.

The Bigger Picture

This case illustrates a critical challenge in rare disease development: early termination rules designed for common conditions may inadvertently halt promising programs serving severely ill but small patient populations. InflaRx’s decision to conduct comprehensive post-hoc analyses demonstrates scientific rigor, while the results validate the C5a/C5aR targeting approach for pyoderma gangrenosum—even if the current trial structure proved inadequate for proof of concept.

The door remains open, but Vilobelimab’s path forward now depends on finding the right partner and proving to regulators that modified endpoints can better capture meaningful benefit in this devastating disease.